BNP Paribas Arbitrage SNC Grows Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

BNP Paribas Arbitrage SNC raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) by 85.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 232,350 shares of the medical equipment provider’s stock after acquiring an additional 107,288 shares during the quarter. BNP Paribas Arbitrage SNC owned approximately 0.34% of Lantheus worth $16,341,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. CWM LLC raised its position in shares of Lantheus by 82.1% in the third quarter. CWM LLC now owns 366 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 165 shares during the period. Wipfli Financial Advisors LLC bought a new stake in Lantheus during the 3rd quarter worth approximately $30,000. Focused Wealth Management Inc bought a new stake in Lantheus during the 3rd quarter worth approximately $63,000. Quadrant Capital Group LLC increased its holdings in Lantheus by 435.6% during the 3rd quarter. Quadrant Capital Group LLC now owns 1,473 shares of the medical equipment provider’s stock worth $104,000 after acquiring an additional 1,198 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in Lantheus during the 3rd quarter worth approximately $116,000. 97.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Mizuho upped their target price on shares of Lantheus from $105.00 to $115.00 and gave the stock a “buy” rating in a report on Friday, February 24th. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Monday, February 27th. JMP Securities initiated coverage on shares of Lantheus in a research note on Wednesday, March 8th. They issued an “outperform” rating and a $120.00 price target for the company. Finally, SVB Leerink initiated coverage on shares of Lantheus in a research note on Wednesday, November 30th. They issued an “outperform” rating for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and a consensus target price of $107.33.

Lantheus Price Performance

LNTH stock opened at $73.02 on Wednesday. The company has a debt-to-equity ratio of 1.25, a current ratio of 2.74 and a quick ratio of 2.59. Lantheus Holdings, Inc. has a one year low of $47.46 and a one year high of $87.47. The stock has a market cap of $4.93 billion, a PE ratio of 214.76 and a beta of 0.64. The firm has a 50 day simple moving average of $60.48 and a two-hundred day simple moving average of $63.76.

Lantheus (NASDAQ:LNTH – Get Rating) last announced its quarterly earnings data on Thursday, February 23rd. The medical equipment provider reported $1.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $0.41. Lantheus had a net margin of 3.00% and a return on equity of 51.60%. The company had revenue of $263.17 million during the quarter, compared to analysts’ expectations of $244.61 million. On average, analysts predict that Lantheus Holdings, Inc. will post 4.46 EPS for the current fiscal year.

Insider Activity

In other news, COO Paul Blanchfield sold 5,250 shares of the company’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $72.56, for a total value of $380,940.00. Following the completion of the sale, the chief operating officer now owns 89,101 shares of the company’s stock, valued at approximately $6,465,168.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Lantheus news, CFO Robert J. Jr. Marshall sold 20,587 shares of the stock in a transaction on Monday, March 6th. The shares were sold at an average price of $72.56, for a total transaction of $1,493,792.72. Following the completion of the sale, the chief financial officer now owns 138,152 shares of the company’s stock, valued at approximately $10,024,309.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Paul Blanchfield sold 5,250 shares of the stock in a transaction on Monday, March 6th. The shares were sold at an average price of $72.56, for a total transaction of $380,940.00. Following the sale, the chief operating officer now directly owns 89,101 shares of the company’s stock, valued at approximately $6,465,168.56. The disclosure for this sale can be found here. In the last 90 days, insiders sold 152,801 shares of company stock valued at $11,138,348. Corporate insiders own 1.60% of the company’s stock.

About Lantheus

(Get Rating)

Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.